Onco-Summaries: Daily Oncology Updates at a Glance

01/06/2026

---

• FDA grants Fast Track to Nouscom’s NOUS‑209, advancing the immunotherapy aimed at intercepting Lynch Syndrome‑associated cancers

---

FDA grants Fast Track to Nouscom’s NOUS‑209, advancing the immunotherapy aimed at intercepting Lynch Syndrome‑associated cancers (Ref)

NOUS‑209, an off‑the‑shelf cancer immunotherapy, received Fast Track status for preventing Lynch Syndrome (LS)‑associated cancers in carriers with mismatch repair mutations

Phase 1b/2 data showed NOUS‑209 was safe, induced broad and durable T‑cell responses, and prevented new advanced adenomas one year post‑treatment

Nouscom plans a registration‑enabling trial to advance NOUS‑209 as the first cancer interception immunotherapy for LS carriers, building on FDA and EMA alignment on the registrational path

Return to Top